To the Editor:
We read with great interest the article of Sabik and colleagues reporting 1-year outcomes with a novel stented bovine pericardial aortic bioprosthesis (PERIGON pivotal trial). It is striking that they report a 1-year prosthesispatient mismatch (PPM) rate of 75.5%, with a severe PPM rate of 30.3%.
Considering the negative impact of PPM on postoperative left ventricular mass regression, functional improvement and quality of life, heart failure, and long-term survival after aortic valve replacement, this high rate of PPM may pose a problem for the widespread use of this novel bioprosthesis. [...]